Small-molecule delivery by nanoparticles for anticancer therapy

Trends in Molecular Medicine

Volumn 16, Issue 12, 2010, Pages 594-602

  Chen, Zhuo Georgia ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CT 2106; DAUNORUBICIN; DOXORUBICIN; IT 101; LIPID; LIPOSOME; MACROGOL; METHOTREXATE; NANOCARRIER; NANOPARTICLE; NK 911; PACLITAXEL; PACLITAXEL POLIGLUMEX; POLYAMIDOAMINE; POLYMER; SMALL MOLECULE ANTICANCER AGENT; SP 1049C; UNCLASSIFIED DRUG; VIRUS VECTOR;

CONTROLLED DRUG RELEASE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; LIPOSOMAL DELIVERY; METASTASIS; MICELLE; MOUSE; NONHUMAN; REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS;

EID: 78649633829     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.08.001     Document Type: Review

References (103)

1. Hofheinz R.D., et al. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005, 16:691-707.
2. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2:347-360.
3. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
4. Matsumura Y., Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009, 100:572-579.
5. Bharali D.J., et al. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int. J. Nanomedicine 2009, 4:1-7.
6. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
7. Venturoli D., Rippe B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am. J. Physiol. Renal. Physiol. 2005, 288:F605-613.
8. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
9. Dreher M.R., et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 2006, 98:335-344.
10. Nomura T., et al. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm. Res. 1998, 15:128-132.
11. Hu-Lieskovan S., et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005, 65:8984-8992.
12. Davis M.E., et al. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
13. Thierry B. Drug nanocarriers and functional nanoparticles: applications in cancer therapy. Curr. Drug Deliv. 2009, 6:391-403.
14. Wang X., et al. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin. 2008, 58:97-110.
15. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
16. Moghimi S.M., et al. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
17. Salvador-Morales C., et al. Multifunctional nanoparticles for prostate cancer therapy. Expert Rev. Anticancer Ther. 2009, 9:211-221.
18. Farokhzad O.C. Nanotechnology for drug delivery: the perfect partnership. Expert Opin. Drug. Deliv. 2008, 5:927-929.
19. Seale-Goldsmith M.M., Leary J.F. Nanobiosystems. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1:553-567.
20. Chithrani, D. B. (2010) Nanoparticles for improved therapeutics and imaging in cancer therapy. Recent Pat Nanotechnol. (in press).
21. Bumb A., et al. Preparation and characterization of a magnetic and optical dual-modality molecular probe. Nanotechnology 2010, 21:175704.
22. Pascu S.I., et al. Towards nanomedicines: design protocols to assemble, visualize and test carbon nanotube probes for multi-modality biomedical imaging. Philos. Transact. A Math Phys. Eng. Sci. 2010, 368:3683-3712.
23. Rosenthal E., et al. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am. J. Clin. Oncol. 2002, 25:57-59.
24. Rivera E., et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J. Clin. Oncol. 2003, 21:3249-3254.
25. Markman M. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin. Pharmacother. 2006, 7:1469-1474.
26. Rivera E. Current status of liposomal anthracycline therapy in metastatic breast cancer. Clin. Breast Cancer 2003, 4(Suppl. 2):S76-83.
27. Rawat M., et al. Nanocarriers: promising vehicle for bioactive drugs. Biol. Pharm. Bull. 2006, 29:1790-1798.
28. Gradishar W.J., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
29. Desai N., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 2006, 12:1317-1324.
30. Li C. Poly(L-glutamic acid)--anticancer drug conjugates. Adv. Drug Deliv. Rev. 2002, 54:695-713.
31. Sabbatini P., et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 2004, 22:4523-4531.
32. Bhatt R., et al. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J. Med. Chem. 2003, 46:190-193.
33. Homsi J., et al. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin. Cancer Res. 2007, 13:5855-5861.
34. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2:347-360.
35. Vasey P.A., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. 1999, 5:83-94.
36. Schluep T., et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 2006, 12:1606-1614.
37. Nakanishi T., et al. Development of the polymer micelle carrier system for doxorubicin. J. Control Release 2001, 74:295-302.
38. Kim T.Y., et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 2004, 10:3708-3716.
39. Nasongkla N., et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006, 6:2427-2430.
40. Nishiyama N., Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 2006, 112:630-648.
41. Svenson S., Tomalia D.A. Dendrimers in biomedical applications--reflections on the field. Adv. Drug Deliv. Rev. 2005, 57:2106-2129.
42. Malik N., et al. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999, 10:767-776.
43. Manchester M., Singh P. Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv. Drug Deliv. Rev. 2006, 58:1505-1522.
44. Singh P., et al. Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J. Nanobiotechnology 2006, 4:2.
45. Flenniken M.L., et al. Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. Chem. Biol. 2006, 13:161-170.
46. Flenniken M.L., et al. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem. Commun. (Camb.) 2005, 447-449.
47. Sapra P., et al. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv. 2005, 2:369-381.
48. Papahadjopoulos D., Gabizon A. Liposomes designed to avoid the reticuloendothelial system. Prog. Clin. Biol. Res. 1990, 343:85-93.
49. Allen T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 1994, 15:215-220.
50. Wagner V., et al. The emerging nanomedicine landscape. Nat. Biotechnol. 2006, 24:1211-1217.
51. Sutton D., et al. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res. 2007, 24:1029-1046.
52. Otsuka H., et al. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev. 2003, 55:403-419.
53. Romberg B., et al. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 2008, 25:55-71.
54. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
55. Gref R., et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B Biointerfaces 2000, 18:301-313.
56. Boddy A.V., et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin. Cancer Res. 2005, 11:7834-7840.
57. Chen M.Y., et al. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J. Neurosurg. 2005, 103:311-319.
58. Pinto Reis C., et al. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006, 2:8-21.
59. Pinto Reis C., et al. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2006, 2:53-65.
60. Soppimath K.S., et al. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70:1-20.
61. Karnik R., et al. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 2008, 8:2906-2912.
62. Chan J.M., et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2009, 30:1627-1634.
63. Ganta S., et al. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control Release 2008, 126:187-204.
64. Bae Y., et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 2005, 16:122-130.
65. Lee E.S., et al. Super pH-sensitive multifunctional polymeric micelle. Nano Lett. 2005, 5:325-329.
66. Zhang W., et al. The encapsulation and intracellular delivery of trehalose using a thermally responsive nanocapsule. Nanotechnology 2009, 20:275101.
67. Sapra P., et al. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin. Cancer Res. 2004, 10:1100-1111.
68. Friedman M., Stahl S. Engineered affinity proteins for tumour-targeting applications. Biotechnol. Appl. Biochem. 2009, 53:1-29.
69. Lofblom J., et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010, 584:2670-2680.
70. Puri A., et al. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J. Liposome Res. 2008, 18:293-307.
71. Alexis F., et al. HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. Chem. Med. Chem. 2008, 3:1839-1843.
72. Sugano M., et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. 2000, 60:6942-6949.
73. Goren D., et al. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer 1996, 74:1749-1756.
74. Heidel J.D., et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5715-5721.
75. Wang X., et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 2009, 3:3165-3174.
76. Seymour L.W., et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34:1629-1636.
77. Seymour L.W., et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20:1668-1676.
78. Duncan R., et al. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr. Relat. Cancer 2005, 12(Suppl. 1):S189-199.
79. Massey K.A., Schnitzer J.E. Caveolae and Cancer. Recent Results Cancer Res. 2010, 180:217-231.
80. Oh P., et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat. Biotechnol. 2007, 25:327-337.
81. John T.A., et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am. J. Physiol. Lung Cell Mol. Physiol. 2003, 284:L187-196.
82. Karmali P.P., et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009, 5:73-82.
83. Zanuy D., et al. The energy landscape of a selective tumor-homing pentapeptide. J. Phys. Chem. B 2008, 112:8692-8700.
84. Agemy L., et al. Nanoparticle-induced vascular blockade in human prostate cancer. Blood 2010, 10.1182/blood-2010-03-274258.
85. Garanger E., et al. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med. Chem. 2007, 7:552-558.
86. Murphy E.A., et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9343-9348.
87. Sugahara K.N., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
88. Blasi F., Carmeliet P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 2002, 3:932-943.
89. Yang L., et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res. 2009, 15:4722-4732.
90. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
91. Nguyen D.X., et al. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9:274-284.
92. Garg A., et al. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm. 2009, 366:201-210.
93. Marchio S., et al. Targeting the extracellular signature of metastatic colorectal cancers. Expert Opin. Ther. Targets 2009, 13:363-379.
94. Wai P.Y., Kuo P.C. The role of Osteopontin in tumor metastasis. J. Surg. Res. 2004, 121:228-241.
95. Elazar V., et al. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int. J. Cancer 2010, 126:1749-1760.
96. Galanzha E.I., et al. Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in vivo detection and killing of circulating cancer stem cells. J. Biophotonics 2009, 2:725-735.
97. ElBayoumi T.A., Torchilin V.P. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin. Cancer Res. 2009, 15:1973-1980.
98. Tian Q., et al. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials 2010, 31:4748-4756.
99. Bartlett D.W., et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15549-15554.
100. Schluep T., et al. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother. Pharmacol. 2006, 57:654-662.
101. Schluep T., et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11394-11399.
102. Cheng J., et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28:869-876.
103. Li C., et al. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother. Pharmacol. 2000, 46:416-422.